

**NATIONAL DEAFNESS AND OTHER COMMUNICATION DISORDERS
ADVISORY COUNCIL**

September 7, 2007

**National Institutes of Health
Bethesda, Maryland**

MINUTES

The National Deafness and Other Communication Disorders Advisory Council convened on September 7, 2007 in Building 31, Conference Room 6, National Institutes of Health (NIH), Bethesda, MD. Dr. James F. Battey, Jr., Director, National Institute on Deafness and Other Communication Disorders (NIDCD), served as Chairperson. In accordance with Public Law 92-463, the meeting was:

Closed: September 7, 2007: 8:30 a.m. to 11:05 a.m. for review of individual grant applications; and

Open: September 7, 2007: 11:05 a.m. to 2:30 p.m., for the review and discussion of program development needs and policy.

Council members in attendance:¹

Ms. Donna Bates Boucher
Dr. Margaretha Casselbrant
Dr. Edward Conture
Dr. Karen Cruickshanks
Dr. Albert Feng
Dr. Charles Greer
Dr. Jennifer Horner

Dr. Nathan Fischel-Ghodsian
Dr. Charlotte Mistretta
Dr. Sharon Moss
Dr. Lorraine Ramig
Dr. Steve Rauch
Dr. Allen Ryan

Council members absent:

Mr. Ronald Lanier
Dr. Susan Goldin-Meadow
Ms. Myrna Orleck-Aiello

Dr. Ernest Weymuller
Dr. William Yost

¹For the record, it is noted that members absent themselves from the meeting when the Council is discussing applications (a) from their respective institutions or (b) in which a real or apparent conflict of interest might occur. This procedure applies only to individual discussion of an application and not to "en bloc" actions.

Ex-Officio Members Not Participating:

Dr. Lucille B. Beck
Dr. John R. Franks
Dr. Michael E. Hoffer

The Council roster is found as Appendix 1.

Various members of the public, as well as NIDCD staff and other NIH staff, were in attendance during the open session of the Council meeting. A complete list of those present for all or part of the meeting is found in Appendix 2.

CLOSED SESSION

I. Call To Order and Opening Remarks Dr. James F. Battey, Jr.

The meeting was called to order by Dr. Battey, Director, NIDCD, who welcomed four new members to the Council, and expressed appreciation to the entire Council for their service and advice. Dr. William Yost has also been appointed to the Council, but was unable to attend today's meeting due to a prior commitment. Dr. Ernest Weymuller, Dr. Susan Goldin-Meadow, Mr. Ronald Lanier, and Ms. Myrna-Orleck-Aiello also had scheduling conflicts which prevented them from attending this meeting.

II. Council Procedures Dr. Craig A. Jordan

Procedural Matters

Dr. Jordan discussed important procedural matters, including requirements imposed by the Government in the Sunshine Act and the Federal Advisory Committee Act. The necessity of members to avoid conflict of interest, or the appearance thereof, was stressed, as was the need to maintain confidentiality concerning the proceedings and materials related to the closed portion of the meeting. Dr. Jordan announced that the Council meeting would be closed for consideration of grant applications during the morning session, but would be open to the public at approximately 11:05 a.m.

III. Council Consideration of Pending Applications

The Council gave special attention to applications involving issues related to protection of human subjects, animal welfare, biohazards and/or women/minority/children representation in study populations as identified by the initial review groups. The Council individually discussed applications being considered for High Program Priority, from New Investigators, and whenever additional discussion was required.

A. Research Project Grant Awards

1. Consideration of Applications: On the Council's agenda was a total of 120 investigator-initiated research grant applications; 100 applications had primary assignment to NIDCD, in the amount of \$29.71 million first-year direct costs. It is anticipated that, of the applications competing at this Council, NIDCD will be able to award grants to R01 applications scoring up to the 20.9 percentile.

B. Special Programs Actions

1. Mentored Patient-Oriented Research Career Development Awards (K23): The Council recommended support of two applications.
2. NIH Pathway to Independence (PI) Award (K99): The Council recommended support of two applications.
3. NIDCD Research Core Center Grants (P30): The Council recommended partial support for two applications.
4. Small Grants (R03): The Council recommended support for eight applications.
5. NIH Support for Conferences and Scientific Meetings (R13): The Council recommended support for one application.
6. NIH Exploratory/Development Research Grant Award (R21): The Council recommended support of seven applications.
7. Small Business Innovation Research Awards (SBIR): The Council recommended support for three Phase I (R43) applications and three Phase II (R44) applications.

**IV. Report of the Board ofDr. Robert Wenthold
Scientific Counselors**

Next, Dr. Battey welcomed Dr. Robert Wenthold, Director of NIDCD's Division of Intramural Research. As stipulated by law, each Institute, Center or Division must provide annually to its National Advisory Council an overview of its intramural research program. The overview should include the reports of the Board of Scientific Counselors, and the responses of the Scientific Director. This presentation is strictly informational; Council members are not asked to recommend approval or disapproval of the reports or to modify them in any way. However, the Council may make recommendations to the Director, NIDCD regarding such research on the basis of the materials provided.

Dr. Wenthold presented the Report of the BSC regarding the review of several intramural laboratories. He then presented his response to the report and responded to questions from Council.

[Executive Secretary Note: During the BSC presentation, attendance was restricted to the Council members; the Director, NIDCD; and a few senior NIDCD administrators.]

OPEN SESSION

V. Opening Remarks.....Dr. Battey

Dr. Battey welcomed additional staff and visitors to the open session of the meeting and introduced four new members of the Council:

- **Dr. Karen Cruickshanks** is Professor, Department of Ophthalmology and Visual Sciences and Professor, Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, where she also serves as Director, Graduate Program in Population Health. Dr. Cruickshanks received her Ph.D. in Epidemiology from the University of Pittsburgh. Her research interests include epidemiology of age-related sensory disorders and the epidemiology of diabetes and its complications; and functional implications of multimodal sensory impairments in older people. Dr. Cruickshanks is the Principal Investigator of a large prospective cohort study of age-related hearing loss and other sensory impairments. She is currently a member of the Association for Research in Vision and Ophthalmology and American Epidemiological Society.
- **Dr. Albert Feng** is Professor of the Beckman Institute and Professor of Molecular and Integrative Physiology, Biophysics and Computational Biology, Bioengineering, and Neuroscience, University of Illinois at Urbana-Champaign. He is also a Richard and Margaret Romano Professorial Scholar, University of Illinois. Dr. Feng received his Ph.D. in Neurobiology and Behavior and in Electrical Engineering from Cornell University. His professional interest is in the area of Neuroscience. Dr. Feng is studying the neural basis of sound communication, using the frog and bat auditory systems as models. He also leads a team of researchers in the development of Biomolecular high-resolution cochlear implants. Dr. Feng has served on several committees, professional organizations and educational teams. He is currently a member of the Association for Research in Otolaryngology.
- **Dr. Charles Greer** is Professor of Neuroscience in the Departments of Neurosurgery and Neurobiology, Yale University School of Medicine, New Haven, CT. At Yale, Dr. Greer also serves as Director, Interdepartmental Neuroscience Graduate Training Program, and Vice Chairman for Research, Department of Neurosurgery. Dr. Greer received his Ph.D. in Neurosciences from the University of Colorado at Boulder. His research focus involves understanding the organization of pathways and projections in the central nervous system and the mechanisms that underlie the establishment of synaptic specificity within circuits. Dr. Greer is internationally recognized for his work on local synaptic circuit organization in the olfactory system and the capacity of the nervous system for plasticity. He is a member of several professional organizations, including the Society for Neuroscience, Association for Chemoreception Sciences and American Association for the Advancement of Science.
- **Dr. Charlotte Mistretta** is Professor, Department of Biologic and Materials Sciences, School of Dentistry, University of Michigan. Dr. Mistretta received her Ph.D. in Biological Science from Florida State University. Her research interests include developmental neurobiology of the peripheral and central taste system; role of neurotrophins and morphogens in sensory ganglion development, morphological and functional differentiation; molecular regulation of taste papilla pattern; nerve-epithelium, and epithelial-mesenchymal interactions during development of the taste papillary and taste bud; role of extracellular matrix molecules in taste organ development and morphogenesis; and the functional

differentiation of taste circuits. She has been an active member with numerous roles at several professional organizations, including the Association for Chemoreception Sciences, Society of Neuroscience, Society for Developmental Biology and American Physiological Society. Dr. Mistretta has served on the Board of Scientific Counselors for NIDCD.

Dr. Battey added that **Dr. William Yost** has also been appointed to the Council, but was unable to attend this meeting. The Institute looks forward to his participation at the January meeting.

Consideration of Minutes of the Meeting of May 18, 2007

Dr. Battey called members' attention to the minutes of the May 18, 2007 meeting of the Advisory Council. The minutes were approved as written.

Confirmation of Dates for Future Council Meetings

Dates for the Council meetings through September 2009 have been established. A list of these meetings was distributed to the Council members and posted on the web site prior to this meeting. The next meeting of Council is scheduled for Friday, January 25, 2008, in Building 31, Conference Room 6 on the NIH campus, Bethesda, Maryland.

VI. Report of the Division of Intramural Research.....Dr. Wenthold

NIH policy requires that the National Advisory Council to each Institute review the activities of their respective intramural program once a year. Dr. Robert Wenthold, Scientific Director of NIDCD's Division of Intramural Research (DIR), presented the 2007 report.

Investigators Tenured in 2007

Two NIDCD investigators, Dr. Dennis Drayna and Dr. Doris Wu, received tenure in NIDCD DIR during FY07.

Dr. Drayna earned his B.A at the University of Wisconsin, and his Ph.D. in Genetics at Harvard Medical School. He completed a postdoctoral fellowship at the University of Utah in the Laboratory of Dr. Ray White, and then worked in private industry. In 1996, he accepted a position as a Visiting Investigator in the National Human Genome Research Institute (NHGRI), and then joined the NIDCD as a Senior Fellow in 1997. He became a tenure-track scientist in 2002. Dr. Drayna's research interests include the genetics of stuttering and chemosensory genetics.

Dr. Doris Wu earned her B.S. in Biology and Chemistry at the University of Wisconsin at Stevens Point. She earned her Ph.D. in Anatomy at UCLA. Her postdoctoral fellowship work was done at Harvard Medical School in the Laboratory of Dr. Connie Cepko. Dr. Wu joined the NIH as a Senior Staff Fellow in 1993, and became a tenure-track scientist in 2000. Dr. Wu's research interests are related to the molecular mechanisms underlying inner ear formation.

These appointments bring the total of tenured NIDCD investigators to fourteen. Other tenured investigators include Dr. Richard Chadwick, Dr. Thomas Friedman, Dr. Barry Horwitz, Dr. Kuni Iwasa, Dr. Bechara Kachar, Dr. Robert Wenthold, Dr. John Northup, Dr. Allen Braun, Dr. Carter Van Waes, Dr. Konrad Noben-Trauth, Dr. Matthew Kelley, and Dr. Andrew Griffith.

New Tenure Track Investigator

Dr. Wenthold announced that Dr. Stephen Brenowitz has joined the DIR as a tenure-track scientist. Dr. Brenowitz earned his B.A. in Molecular Biology at Berkeley in 1989, and then his Ph.D. in Neuroscience at the University of Wisconsin, in 2001. He completed his postdoctoral fellowship at the Department of Neurobiology, Harvard Medical School in 2007. He has authored twelve research publications. His research interests include the synaptic plasticity and integration in neural circuits of the auditory system. Dr. Brenowitz will have his lab in Building 50, adjacent to the labs of Drs. Kachar, Sieving, and Wenthold.

Board of Scientific Counselors

Dr. Wenthold updated the Council on the membership of the Board of Scientific Counselors. Membership has remained unchanged in the past year. The BSC is chaired by Dr Paul Fuchs of Johns Hopkins University. Other members include Dr. Miriam Meisler, University of Michigan; Dr. Nirupa Chaudhari, University of Miami, Dr. Gary Schoenwolf, University of Utah, Dr. Charles Liberman, Harvard University; Dr. Richard Cheney, University of North Carolina; Dr. Richard Chole, Washington University; and Dr. Ron Hoy, Cornell University.

VII. Report of the Director, NIDCD Dr. Battey

Budget Considerations:

Dr. Battey began his presentation with a breakdown of the President's NIDCD Budget Request for FY 2008. However, based on the uncertainty associated with the congressional approval of the FY2008 budget request, the NIDCD is currently using the FY2007 budget level for planning purposes. Based on this model, there would be \$277.2 million available for research project grants. Dr. Battey detailed how the \$277.2 million will be allocated. From this total, \$9.6 million is reserved for Small Business Research grants, \$1.5 million for administrative supplements, \$203.5 million for commitments to noncompeting grants, \$1.4 million for carryover commitments from prior Council meetings, and \$14.5 million for program requirements. An additional estimated \$4.0 million is available from end of year FY07 funds. Twenty percent of the remaining \$50.8 million is designated for High Program Priority (HPP). Consequently, there are \$40.6 million available for the initial payline across the year's three Council meetings. This should allow funding of applications up to the 20.9 percentile. A copy of the slides Dr. Battey used for his budget presentation is included in these minutes as Appendix 3.

VIII. Report of the Director, Division of Extramural Activities Dr. Jordan

Dr. Jordan presented the Report of the Director, Division of Extramural Activities.

New Staff

Dr. Jordan introduced Dr. Christopher Moore, who joined the NIDCD in July as a Scientific Review Administrator. Dr. Moore earned his Ph.D. in Speech Sciences from Purdue University, and has held faculty positions at Wichita State University, University of Pittsburgh, and University of Washington. Before coming to the NIH, he served on NIDCD and CSR study sections and has received grant support from NINCDS and NIDCD. His research interests include many aspects of speech including production, development, physiology, pathology; sensorimotor integration; and additional areas of neuroscience.

Enhancing Peer Review at the NIH

Dr. Jordan discussed the recent “Self–Study by the NIH in Partnership with the Scientific Community to Strengthen Peer Review in Changing Times.” The increasing breadth, complexity and interdisciplinary nature of biomedical science are creating new challenges for the system used by NIH to support biomedical and behavioral research. Peer review is a key component of this system. On June 8, 2007, NIH Director, Dr. Elias Zerhouni, called upon leaders from across the scientific community and NIH to join a trans-NIH effort to examine the two-level NIH peer review system. The effort involves both external and internal working groups:

- External – The Advisory Council to the Director (ACD) Working Group on Peer Review, co-chaired by Dr. Keith Yamamoto, Executive Vice Dean, School of Medicine, UCSF and Dr. Lawrence Tabak, Director, National Institute of Dental and Craniofacial Research, NIH
- Internal – The Steering Committee Working Group on Peer Review co-chaired, by Dr. Tabak and Dr. Jeremy Berg, Director, National Institute of General Medical Sciences, NIH.

The two working groups are seeking broad input from both external and internal communities. NIH will seek input from the scientific community, including investigators, scientific societies, grantee institutions and voluntary health organizations. NIH will also seek input from its own staff. The many activities include:

- External Request for Information (RFI) (July–September). See RFI questions at: <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-074.html>;
- Three Regional Meetings – Chicago, New York City and San Francisco (September–October);
- Two External Consultative meetings in Washington, D.C. with Professional Societies and Advocacy Groups (July–October);
- Science Liaisons selected by the ACD working group to enhance outreach to stakeholders and to solicit opinion (July–October);
- Internal Survey for NIH staff (July–September);
- Steering Committee Working Group Internal NIH Staff Consultative Meetings (July–August);
- Solicit Institute and Center Director Prior Experiments and Ideas (July–August).

Once the information gathering is complete, analyses and summaries of the various inputs, data collected and breadth of ideas will be provided to NIH leadership to determine next steps, including

piloting, associated evaluations, and development of an implementation plan. Further details about the study can be found at <http://enhancing-peer-review.nih.gov/>.

NIH Director's New Innovator Award Program

This new award program, open to new investigators, was launched by the NIH in February 2007 with additional resources provided in the 2007 Joint Resolution. The goal is to fund exceptionally innovative research with potential for significant impact. Awards will provide up to \$1.5 million direct costs over five years and the NIH expects to fund more than 14 awards in September.

To qualify, the new investigator must have received his/her most recent doctoral degree or completed medical internship and residence in 1997 or later; must never have been a PI on an R01 or equivalent NIH grant; and must hold an independent research position at a U.S. institution as of September 20, 2007. Awardees will be required to commit at least 30% of their research effort to activities supported by the New Innovator Award (staff will verify at time of award).

Applications required a novel structure, with an abstract, a 2 page biographical sketch, a list of current and pending research support, and a ten-page essay. The essay should describe the scientific problem, significance and potential impact; suitability for New Innovator Award, and describe the innovativeness of the project, and alternatives if approaches are not successful. Finally, the qualifications of the investigator and evidence for creativity and innovativeness must be outlined in the essay. Review criteria will specifically address impact, innovation, and creativity.

Almost 2200 applications were received for the May deadline and each went through a multi-stage peer review process. A group of IC Directors and program staff will develop a funding plan for consideration by the Advisory Committee to the Director.

Additional information about this award can be found at http://grants.nih.gov/grants/new_investigators/innovator_award/.

IX. Report of the Director, Division of Scientific ProgramsDr. Judith Cooper

Dr. Cooper, Director Division of Scientific Programs introduced Dr. Christopher Platt, who discussed the Research Core Centers (P30) Program.

Dr. Platt outlined key features of the Research Core Centers (P30) program, which include the following:

- support one or more research cores;
- provide centralized resources and facilities shared by investigators with existing research projects;
- promote cooperative interaction among basic science and/or clinical investigators;
- may include multi-disciplinary, multi-institutional and regional collaborations;
- award cap depends on size of R01-supported research base (can be \$300,000, \$400,000, or \$500,000 per year for five years);
- includes opportunities for translational research (NOT-DC-05-001);
- specifically facilitates translating research advances into practical clinical applications;
- particularly encourages cooperation among basic science and/or clinical investigators;

- NIDCD managed peer review, 3 cycles/year; allows partial awards.

In FY07, there have been eighteen active P30s, totaling more than \$5M per year. There was a total of 45 research cores in FY07, including one human non-clinical support core and 15 human clinical support cores. Program costs have changed significantly since the onset of the program, and decreased costs are projected over the next few years.

Beginning in 2006 the P30 program was closed to new applications and only renewals, amended resubmissions and supplements were accepted. More recently, there has been some interest expressed by new groups and the budgetary pressure on the NIDCD's Centers line has relaxed.

Dr. Platt indicated this new information and the need for a competitive review to include new entrants along with renewals to bring in fresh ideas and technologies has convinced the NIDCD to expand the P30 program to allow new applications. A notice will be published in the NIH Guide to Grants and Contracts that announces that from 2008 on, new applications will be accepted only once per year (January 25); renewals and resubmissions will continue to be accepted three times per year.

[Executive Secretary Note: The P30 announcement was published on September 11, 2007 and can be accessed at: <http://grants.nih.gov/grants/guide/notice-files/NOT-DC-08-001.html>]

X. Scientific Presentation.....Dr. Alec Salt

Dr. Battey introduced Dr. Alec Salt, Professor, Department of Otolaryngology, Washington University School of Medicine, St. Louis, Missouri. Dr. Salt accepted NIDCD's invitation to discuss his research in a presentation entitled "Optimizing Intratympanic Drug Therapies of the Ear." Following is an abstract of Dr. Salt's presentation:

"Optimizing Intratympanic Drug Therapies of the Ear"

Intratympanic drug therapy consists of injecting a drug solution through the tympanic membrane into the middle ear cavity. A portion of the drug subsequently diffuses through the round window membrane into the fluid spaces of the inner ear. Intratympanic therapy is increasingly being used in the clinic to treat auditory and vestibular disorders, such as Meniere's disease, idiopathic sudden sensorineural hearing loss and tinnitus, and to reduce cochlear implant insertion trauma. It remains difficult, however, to determine the appropriate dosing for each drug used clinically. This must take into account the numerous variables associated with the delivery methods, application protocols and drug formulations. Computer models of drug dispersion in the inner ear fluids have been developed that allow both experimental and clinical data to be interpreted quantitatively. In recent years, parameters for the model have been derived by comparing results from the model with pharmacokinetic measurements of the cochlear fluids in animals. Using these parameters, the model can be used to predict drug levels in humans. We have now estimated the perilymph levels of gentamicin produced by intratympanic therapy in humans, based on the application protocols described in 20 published clinical studies. The calculated gentamicin levels achieved at the cochlear locations corresponding to the auditory frequencies tested were compared with the reported hearing sensitivity changes for 569 individual patients. For "one-shot" application protocols, there appeared to be no significant correlation of hearing loss with the gentamicin level in perilymph. Rather, hearing changes appeared to be evenly distributed with gains and losses probably originating from random fluctuations associated with the disease rather than from gentamicin treatment. Application protocols using repeated injections generated higher gentamicin levels in the regions of the cochlea tested and resulted in increased occurrence of hearing losses attributable to the treatment. This analysis demonstrates the difficulties associated with attempts to

establish the drug dose based on patient studies with limited numbers and with drug dosing over a very limited range. For drugs that are not toxic to the ear, establishing the most effective dosing protocol may be even more difficult. Computer modeling provides a rational basis to establish and compare dosing protocols in humans.

(Research supported by NIH/NIDCD grant DC01368.)

XI. Scientific Presentation..... Dr. Allen Ryan

Next, Dr. Battey introduced Council member Dr. Allen F. Ryan, who also agreed to discuss his research in a presentation entitled “The Life, Death and Afterlife of the Hair Cell.” Dr. Ryan is Professor of Surgery/Otolaryngology at the Departments of Surgery/Otolaryngology and Neurosciences, UCSD of Medicine, La Jolla, CA. Following is an abstract of Dr. Ryan’s presentation:

“The Life, Death and Afterlife of the Hair Cell”

The hair cell is the signature cell of the inner ear, responsible for transduction of auditory and vestibular stimuli into neuronal impulses in the VIIIth nerve, and unique in its structure and function from any other cell in the body. The hair cell is generated and maintained by a unique pattern of gene expression. However, our knowledge of gene regulation in hair cells is minimal. A critical gene in this process is POU4F3, which encodes a transcription factor that directs the late differentiation of hair cells and is required for their survival. Using transgenic mouse models in which expression of green fluorescent protein (GFP) is driven by POU4F3 upstream DNA, we have evaluated the regulation of POU4F3 expression in hair cells. We have defined a 2 kb region located between 6.5 and 8.5 kb 5’ to the coding region that is required for gene expression in this cell type. The region includes a motif, conserved across several mammalian species, that includes binding sites for several other transcription factors, including Atoh1, Sp1, GATA3 and an E2a factor. Atoh1 and Sp1 strongly activate this region, and appear to act in synergy with the E2a factor E47. POU4F3 also appears to autoregulate its own promoter. This and other data represent the first attempt to define a combinatorial code that directs gene expression to hair cells.

Using our transgenic model of GFP-positive hair cells, we also explored the fate of these cells after damage by ototoxic agents in vitro. We have found that many hair cells can survive damage by such agents, surviving beneath the surface of the epithelium but lacking the apical specializations that otherwise define the cell type. If these cells can be induced to self-repair, they represent a potential source of hair cell regeneration. We have also explored hair cell replacement by transplantation in vitro. GFP-positive hair cells from vestibular maculae were transplanted into GFP-negative, gentamicin-damaged maculae. We found that about 50% of hair cells readily survived transplantation. However, integration into the sensory epithelium, and growth of a new stereociliary bundle, was observed only for hair cells harvested at a critical period of embryonic development. This suggests that hair cell transplantation may be possible. However, this may occur only if the cells are at an appropriate stage of development.

(Supported by NIH/NIDCD grant DC00139, the Research Service of the VA, and NOHR).

XII. Adjournment: The meeting was adjourned at 2:30 p.m. on September 7, 2007.



XIII. Certification of Minutes

We certify that, to the best of our knowledge, the foregoing minutes and attachments are accurate and correct.²

Oct. 29, 2007



Craig A. Jordan, Ph.D.
Executive Secretary
National Deafness and Other Communication
Disorders Advisory Council

November 1, 2007



James F. Battey, Jr., M.D., Ph.D.
Chairman
National Deafness and Other Communication
Disorders Advisory Council

Director
National Institute on Deafness and
Other Communication Disorders

Jeannie Combs
Contractor
NDCD Advisory Council

² These minutes will be formally considered by the NDCD Advisory Council at its next meeting; corrections or notations will be incorporated in the minutes of that meeting.

APPENDICES

		PAGE
APPENDIX 1	NDCD Advisory Council Roster	13
APPENDIX 2	List of Meeting Attendees.....	15
APPENDIX 3	NIDCD Director's Report Slides	17

Roster
National Deafness and Other Communication Disorders Advisory Council

Chairperson
James F Battey, Jr., M.D., Ph.D., Director
National Institute on Deafness and Other Communication Disorders
Bethesda, Maryland 20892

<p>BATES-BOUCHER, Donna President Bates Group, Inc. Eight Hyde Park Circle Denver, CO</p>	<p>2009</p>	<p>GOLDIN-MEADOW, Susan J., Ph.D. Beardsley Ruml Distinguished Service Professor Department of Psychology Division of Social Sciences University of Chicago Chicago, IL</p>	<p>2008</p>
<p>CASSELBRANT, Margaretha L., M.D., Ph.D. Director Division of Pediatric Otolaryngology Children's Hospital of Pittsburgh School of Medicine Pittsburgh, PA</p>	<p>2010</p>	<p>GREER, Charles A., Ph.D. Professor of Neuroscience Department of Neurosurgery Yale University School of Medicine New Haven, CT</p>	<p>2011</p>
<p>CONTURE, Edward G., Ph.D. Professor and Director, Graduate Studies Vanderbilt University Medical Center DHSS Graduate Studies and Research Nashville, TN</p>	<p>2008</p>	<p>HORNER, Jennifer, J.D., Ph.D. Associate Professor and Chair Department of Rehabilitation Sciences Medical University of South Carolina Charleston, SC</p>	<p>2010</p>
<p>CRUICKSHANKS, Karen J., Ph.D. Professor Department of Ophthalmology and Visual Sciences University of Wisconsin School of Medicine and Public Health Madison, WI</p>	<p>2011</p>	<p>LANIER, Ronald L. Director Virginia Department for the Deaf and Hard of Hearing Commonwealth of Virginia Richmond, VA</p>	<p>2008</p>
<p>FENG, Albert S., Ph.D., MS Professor Department of Molecular and Integrative Physiology University of Illinois Urbana-Champaign Urbana, IL</p>	<p>2011</p>	<p>MISTRETTA, Charlotte M., Ph.D. Professor Department of Biologic and Materials Sciences University of Michigan School of Dentistry Ann Arbor, MI</p>	<p>2011</p>
<p>FISCHEL-GHODSIAN, Nathan, M.D. Professor Department of Pediatrics Cedars-Sinai Medical Center University of California, Los Angeles Los Angeles, CA</p>	<p>2009</p>		

MOSS, Sharon E., Ph.D. 2008
Director
Scientific Programs and Research
Development
Science and Research Unit
American Speech-Language-Hearing Assoc.
Rockville, MD

ORLECK-AIELLO, Myrna "Mo" 2009
CEO/President
Abacus N Bytes, Inc.
D/B/A TCS Associates
Wheaton, MD

RAMIG, Lorraine, Ph.D., CCC-SLP 2010
Professor
Department of Speech Language Hearing Sciences
University of Colorado, Boulder
Boulder, CO

RAUCH, Steven D., M.D. 2010
Associate Professor Otolaryngology
Department of Otology & Laryngology
Harvard Medical School
Massachusetts Eye and Ear Infirmary
Boston, MA

RYAN, Allen F., Ph.D. 2009
Professor of Surgery/Otolaryngology
Department of Surgery
University of California at San Diego
La Jolla, CA

WEYMULLER, Ernest A., M.D. 2009
Chair and Professor
Department of Otolaryngology-HNS
University of Washington
School of Medicine
Seattle, WA

YOST, William A., Ph.D. 2011
Chair of Speech and Hearing Science
Department of Speech and Hearing Science
Arizona State University
Tempe, AZ

EX-OFFICIO MEMBERS:

BECK, Lucille B., Ph.D.
Director
Audiology & Speech Pathology Service (117A)
Department of Veterans Affairs
Washington, DC

FRANKS, John R., Ph.D.
Chief, Bioacoustics and Occupational
Vibration Section
Physical Agent Effects Branch
Division of Biomedical and Behavioral Science
National Inst for Occupational Safety & Health
Cincinnati, OH

HOFFER, Michael E., M.D.
Co-Director
Department of Defense Spatial Orientation Center
Department of Otolaryngology
Naval Medical Center
San Diego, CA

LEAVITT, Michael O.
Secretary
Department of Health and
Human Services
Hubert H. Humphrey Building
Washington, DC

ZERHOUNI, Elias Adam, M.D.
Director
National Institutes of Health
Bethesda, MD 20892

EXECUTIVE SECRETARY

JORDAN, Craig A., Ph.D.
Director
Division of Extramural Research, NIDCD
Bethesda, MD

Rev. 08/2007

Appendix 2

ATTENDANCE LIST

Other than Council members, attendees at the September 7, 2007 Council meeting included:

NIDCD Staff:

Office of Health Communication and Public Liaison

Miranda-Acevedo, Robert, Technical Writer

Joy, Linda, Science Writer

Wenger, Jenny, Technical Writer

Office of Administration

Kerr, W. David, Executive Officer

Financial Management Branch

Rotariu, Mark, Chief

Esterlin, Michelle, Emerging Leader

Lee, Mimi, Budget Analyst

Science Policy and Planning Branch

Wong, Baldwin, Chief

Montney, Lisa, Science Policy Analyst

Division of Extramural Activities

Jordan, Craig A., Ph.D., Director

Stephenson, Nanette, Program Assistant

Grants Management Branch

Myers, Christopher, Chief

Dabney, Sherry, Grants Management Officer

Doan, Hoai, Grants Management Specialist

Garcia, Maria, Grants Management Specialist

McNamara, Castilla, Ph.D., Grants Management Specialist

Myrbeck, Eddie, Grants Management Specialist

Ranney, Meigs, Grants Management Officer

Scientific Review Branch

Stick, Melissa, Ph.D., M.P.H., Chief

Livingston, Christine, Ph.D., Scientific Review Administrator

Moore, Christopher, Ph.D., Scientific Review Administrator

Singh, Sheo, Ph.D., Scientific Review Administrator

Yang, Shiguang A., Ph.D., Scientific Review Administrator

Division of Scientific Programs

Cooper, Judith, Ph.D., Director

Voice, Speech, Language, Smell and Taste Branch

Cooper, Judith, Ph.D., Program Director, Language Program

Davis, Barry, Ph.D., Program Director, Smell and Taste Program

Shekim, Lana, Ph.D., Program, Director, Voice & Speech Program

Sklare, Daniel A., Ph.D., Program Director, Research Training and
Development Program

Hearing and Balance/Vestibular Branch

Donahue, Amy, Ph.D., Chief

Freeman, Nancy, Ph.D., Program Director, Hearing

Luethke, Lynn, Ph.D., Program Director, Hearing

Miller, Roger, Ph.D., Program Director, Hearing

Platt, Christopher, Ph.D., Program Director, Balance/Vestibular

Watson, Bracie, Ph.D., Program Director, Hearing

Translational Research Branch

Chin, Ling, M.D., MPH, Chief

Hoffman, Howard, Program Director for Epidemiology & Biostatistics

Division of Intramural Research

Wenthold, Robert, Ph.D., Director

Division of Extramural Administrative Support, OER, NIH

Holmes, Debbie, Extramural Support Assistant

Farrington, Torrance, Extramural Support Assistant

Center for Scientific Review, NIH

Clayton, Edwin, Ph.D., Scientific Review Administrator

Kenshalo, Daniel, Ph.D., Scientific Review Administrator

Melchior, Christine, Ph.D., Chief, Integrative, Functional, and Cognitive Neuroscience IRG

Ni, Weijia, Ph.D., Scientific Review Administrator

Tian, Biao, Ph.D., Scientific Review Administrator

Office of Director, NIH

Rogers, Joyce, Office of Budget

Others

Salt, Alec, Ph.D., Washington University School of Medicine

Thomas, Kate, American Academy of Audiology

Dennis, Kyle, Ph.D., Veteran's Administration

Appendix 3

NIDCD Director's Report Slides

As Presented By

James F. Battey, Jr., M.D., Ph.D.
Director, NIDCD

NIDCD Advisory Council Meeting

September 7, 2007

National Institute on Deafness and Other Communication Disorders

**September 2007 Council
Budget Mechanism
(Dollars in thousands)**

<i>Budget Mechanism</i>	<u>FY 2007 Appropriation</u>		<u>President's Request</u>	
	<i>Number</i>	<i>Amount</i>	<i>Number</i>	<i>Amount</i>
Research Projects				
Noncompeting	633	\$199,249	625	\$198,134
Admin. Supplements	(26)	1,250	(23)	1,050
Competing	231	67,130	225	65,275
Subtotal	<u>864</u>	<u>267,629</u>	<u>850</u>	<u>264,459</u>
SBIR/STTR	<u>30</u>	<u>9,600</u>	<u>28</u>	<u>9,000</u>
Subtotal, RPG's	894	277,229	878	273,459
Research Centers	20	17,252	20	17,079
Other Research	<u>63</u>	<u>10,156</u>	<u>65</u>	<u>9,962</u>
Total Research Grants	977	304,637	963	300,500
Individual Training	154	5,900	141	5,418
Institutional Training	187	7,700	180	7,417
R & D Contracts	52	22,420	50	21,961
Intramural Research		34,905		35,032
Research Mgmt. & Support		18,106		18,179
NIH Roadmap		<u>0</u>		<u>5,175</u>
TOTAL		\$393,668		\$393,682

National Institute on Deafness and Other Communication Disorders

September 2007 Council

Competing Research Project Grants

(Dollars in thousands)

Total RPG Funds FY08 estimate	\$277,229
Less SBIR/STTR estimate	-9,600
Less Administrative Supplements estimate	-1,500
Less Noncompeting estimate	-203,470 assumes zero reduction
Less FY08 "Carryover" Commitments from prior Council meetings	-1,356 three from May 07 Council
Less FY08 Program Requirements	-14,500
Plus FY07 funds	4,000 available for Sept 07 Council

Total	\$50,803		
	↙	↘	
	<u>20% HPP</u>	<u>80% Regular</u>	
For FY 2008	\$10,161	\$40,642	
	\$3,387	\$13,547	33%